Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has Toni K. Choueiri's publication output changed over time?
ScholarIQpublication output · 2015–2018
Output grew0% over the shown period — from 1 works in 2015 to 1 in 2018.
1
1
1
201520172018
What are the most-cited papers on Toni K. Choueiri?
ScholarIQmost cited works
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Bernard Escudier, Ray McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Toni K. Choueiri, Howard Gurney, Frede Donskov, Petri Bono, John Wagstaff, Thomas Gauler, Takeshi Ueda, Yoshihiko Tomita, Fabio A.B. Schutz, Christian Kollmannsberger, James Larkin, Alain Ravaud, Jason S. Simon, Li-An Xu, Ian M. Waxman, Padmanee Sharma
New England Journal of Medicine. 20155,914 CitationsOPEN ACCESS
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer, Nizar M. Tannir, Ray McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, Thomas Powles, Frede Donskov, Victoria Neiman, Christian Kollmannsberger, Pamela Salman, Howard Gurney, Robert D. Hawkins, Alain Ravaud, Marc‐Oliver Grimm, Sergio Bracarda, Carlos H. Barrios, Yoshihiko Tomita, Daniel Castellano, Brian I. Rini, Allen C. Chen, Sabeen Mekan, M. Brent McHenry, Megan Wind‐Rotolo, Justin Doan, Padmanee Sharma, Hans J. Hammers, Bernard Escudier
New England Journal of Medicine. 20184,676 CitationsOPEN ACCESS
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Joaquim Bellmunt, Ronald de Wit, David J. Vaughn, Yves Fradet, Jae‐Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel Ángel Climent, Daniel P. Petrylak, Toni K. Choueiri, Andrea Necchi, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stéphane Culine, Cora N. Sternberg, Yabing Mai, Christian Poehlein, Rodolfo F. Perini, Dean F. Bajorin
New England Journal of Medicine. 20173,413 CitationsOPEN ACCESS
Related on ScholarIQ
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Paper
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Paper
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Paper
Cancer Immunotherapy and Biomarkers
Topic
Cancer Genomics and Diagnostics
Topic
Bladder and Urothelial Cancer Treatments
Topic